Table 2 Laboratory parameters of patients with events versus without events during hospitalization.
From: Prognostic role of neoplastic markers in Takotsubo syndrome
Admission | 72 h | Discharge | |||||||
|---|---|---|---|---|---|---|---|---|---|
In-hospital MACE | No events | p | In-hosp. MACE | No events | p | In-hosp MACE | No events | p | |
Troponin I (ng/mL) | 4.78 ± 7.65 | 3.03 ± 2.78 | 0.14 | 2.75 ± 6.49 | 1.46 ± 1.85 | 0.19 | 0.28 ± 0.43 | 0.18 ± 0.23 | 0.21 |
CRP (mg⁄L) | 64.34 ± 42.29 | 72.2 ± 58.1 | 0.13 | 71.08 ± 41.12 | 86.2 ± 53.4 | 0.11 | 38.01 ± 39.1 | 14.92 ± 18.13 | 0.05 |
NT-BNP (pg/mL) | 19,821.5 ± 16,377 | 12,975.7 ± 14,619 | 0.05 | 13,660 ± 11,923 | 13,274 ± 17,006 | 0.92 | 14,333 ± 19,198.4 | 5653 ± 8474 | 0.03 |
Neoplastic markers | |||||||||
CEA (ng/mL) | 4.29 ± 6.25 | 2.18 ± 1.51 | 0.03 | 4.36 ± 6.30 | 5.74 ± 19.73 | 0.72 | 4.62 ± 7.76 | 1.71 ± 1.39 | 0.05 |
CA 15–3 (UI/mL) | 24.35 ± 11.11 | 21.77 ± 10.51 | 0.26 | 22.80 ± 10.86 | 20.08 ± 10.19 | 0.32 | 22.87 ± 11.57 | 19.70 ± 9.51 | 0.24 |
CA-19–9 (UI/mL) | 21.61 ± 27.4 | 26.32 ± 108.8 | 0.78 | 28.58 ± 43.45 | 38.52 ± 147.07 | 0.72 | 31.16 ± 55.06 | 9.98 ± 9.82 | 0.04 |
Interleukins | |||||||||
IL1 ALFA (pg/mL) | 0.60 ± 0.26 | 0.89 ± 0.91 | 0.11 | 0.96 ± 1.6 | 0.83 ± 0.83 | 0.74 | 0.76 ± 0.48 | 1.06 ± 1.7 | 0.48 |
IL 2 (UI/mL) | 2.61 ± 2.99 | 3.44 ± 7 | 0.52 | 2.80 ± 2.9 | 3.59 ± 4.2 | 0.44 | 4.91 ± 10.95 | 5.18 ± 5.31 | 0.91 |
IL 6 (pg/mL) | 72.10 ± 199.8 | 24.64 ± 58.5 | 0.14 | 29.82 ± 39.12 | 23.02 ± 53.74 | 0.58 | 25.02 ± 31.14 | 7.94 ± 8.05 | 0.05 |
IL 10 (pg/mL) | 10.38 ± 35.89 | 2.7 ± 3.34 | 0.17 | 2.07 ± 1.99 | 2.33 ± 2.74 | 0.68 | 2.56 ± 3.12 | 2.30 ± 2.99 | 0.74 |
